0000947871-24-001036.txt : 20241226 0000947871-24-001036.hdr.sgml : 20241226 20241226163122 ACCESSION NUMBER: 0000947871-24-001036 CONFORMED SUBMISSION TYPE: SCHEDULE 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20241226 DATE AS OF CHANGE: 20241226 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Passage BIO, Inc. CENTRAL INDEX KEY: 0001787297 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822729751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91451 FILM NUMBER: 241581410 BUSINESS ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 2678660312 MAIL ADDRESS: STREET 1: ONE COMMERCE SQUARE STREET 2: 2005 MARKET STREET, 39TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ORBIMED ADVISORS LLC CENTRAL INDEX KEY: 0001055951 ORGANIZATION NAME: IRS NUMBER: 133976876 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SCHEDULE 13D/A BUSINESS ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (212) 739-6400 MAIL ADDRESS: STREET 1: 601 LEXINGTON AVENUE STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SCHEDULE 13D/A 1 primary_doc.xml SCHEDULE 13D/A 0000947871-20-000199 0001055951 XXXXXXXX LIVE 5 Common Stock 12/20/2024 false 0001787297 702712100 Passage BIO, Inc.
One Commerce Square, 2005 Market Street 39th Floor Philadelphia PA 19103
OrbiMed Advisors LLC 2127396400 601 Lexington Avenue 54th Floor New York NY 10022 0001055951 N ORBIMED ADVISORS LLC AF N DE 0.00 7404869.00 0.00 7404869.00 7404869.00 N 12.0 IA 0001760648 N ORBIMED CAPITAL GP VII LLC AF N DE 0.00 7404869.00 0.00 7404869.00 7404869.00 N 12.0 OO 0001157524 N ORBIMED CAPITAL LLC AF N DE 0.00 0.00 0.00 0.00 0.00 N 0 IA Common Stock Passage BIO, Inc. One Commerce Square, 2005 Market Street 39th Floor Philadelphia PA 19103 This Amendment No. 5 ("Amendment No. 5") to Schedule 13D supplements and amends the Statement on Schedule 13D of OrbiMed Advisors LLC ("OrbiMed Advisors"), OrbiMed Capital GP VII LLC ("OrbiMed GP"), and OrbiMed Capital LLC ("OrbiMed Capital") (collectively, the "Reporting Persons") originally filed with the Securities and Exchange Commission (the "SEC") on March 9, 2020, as amended by Amendment No. 1 filed with the SEC on January 28, 2021, Amendment No. 2 filed with the SEC on May 5, 2022, Amendment No. 3 filed with the SEC on June 29, 2023, and Amendment No. 4 filed with the SEC on April 12, 2024. This Amendment No. 5 is being filed to report that the beneficial ownership of the outstanding shares of common stock, $0.0001 par value per share ("Shares"), of Passage BIO, Inc. (the "Issuer") held by the Reporting Persons decreased by more than 1% as a result of the transactions described in Item 5(c) below. OrbiMed Advisors, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended. OrbiMed GP, a limited liability company organized under the laws of Delaware. OrbiMed Capital, a limited liability company organized under the laws of Delaware and a registered investment adviser under the Investment Advisers Act of 1940, as amended. Carl L. Gordon, a United States citizen. Sven H. Borho, a German and Swedish citizen. W. Carter Neild, a United States citizen. Geoffrey C. Hsu, a United States citizen. C. Scotland Stevens, a United States citizen. David P. Bonita, a United States citizen. Peter A. Thompson, a United States citizen. Matthew S. Rizzo, a United States citizen. Trey Block, a United States citizen. 601 Lexington Avenue, 54th Floor, New York, New York 10022. OrbiMed Advisors is the managing member or general partner of certain entities as more particularly described in Item 6 below. OrbiMed GP is the general partner of a limited partnership as more particularly described in Item 6 below. OrbiMed Capital is the investment adviser of certain entities as more particularly described in Item 6 below. Carl L. Gordon is a member of OrbiMed Advisors and OrbiMed Capital. Sven H. Borho is a member of OrbiMed Advisors and OrbiMed Capital. W. Carter Neild is a member of OrbiMed Advisors and OrbiMed Capital. Geoffrey C. Hsu is a member of OrbiMed Advisors and OrbiMed Capital. C. Scotland Stevens is a member of OrbiMed Advisors and OrbiMed Capital. David P. Bonita is a member of OrbiMed Advisors and OrbiMed Capital. Peter A. Thompson is a member of OrbiMed Advisors and OrbiMed Capital. Matthew S. Rizzo is a member of OrbiMed Advisors and OrbiMed Capital. Trey Block is the Chief Financial Officer of OrbiMed Advisors and OrbiMed Capital. Not applicable. Not applicable. Item 2(a) is incorporated herein by reference. Not applicable. The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries, (c) a sale or transfer of a material amount of the assets of the Issuer or any of its subsidiaries, (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) any material change in the Issuer's capitalization or dividend policy of the Issuer, (f) any other material change in the Issuer's business or corporate structure, (g) any change in the Issuer's charter or bylaws or other instrument corresponding thereto or other action which may impede the acquisition of control of the Issuer by any person, (h) causing a class of the Issuer's securities to be deregistered or delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association, (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act or (j) any action similar to any of those enumerated above. The following disclosure is based upon 61,767,286 outstanding Shares of the Issuer, as set forth in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on November 13, 2024. As of the date of this filing, OrbiMed Private Investments VII, LP ("OPI VII"), a limited partnership organized under the laws of Delaware, holds 7,404,869 Shares constituting approximately 12.0% of the issued and outstanding Shares. OrbiMed GP is the general partner of OPI VII, pursuant to the terms of the limited partnership agreement of OPI VII, and OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. As a result, OrbiMed Advisors and OrbiMed GP share power to direct the vote and disposition of the Shares held by OPI VII and may be deemed directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the Shares held by OPI VII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII. As of the date of this filing, Worldwide Healthcare Trust PLC ("WWH"), a publicly listed investment trust organized under the laws of England, ceased to hold any Shares. OrbiMed Capital is the investment advisor of WWH. As a result, OrbiMed Capital has the power to direct the vote and disposition of the Shares previously held by WWH and may be deemed directly or indirectly, including by reason of mutual affiliation, to be the beneficial owner of the Shares previously held by WWH. OrbiMed Capital disclaims any beneficial ownership over the Shares of the other Reporting Persons. OrbiMed Capital exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by WWH. Item 5(a) is incorporated by reference herein. On December 4, 2024, OPI VII sold 76,200 Shares at a weighted average price of $0.79 per Share. On December 4, 2024, WWH sold 19,800 Shares at a weighted average price of $0.79 per Share. On December 6, 2024, OPI VII sold 20,903 Shares at a weighted average price of $0.82 per Share. On December 6, 2024, WWH sold 5,405 Shares at a weighted average price of $0.82 per Share. On December 9, 2024, OPI VII sold 54,181 Shares at a weighted average price of $0.84 per Share. On December 9, 2024, WWH sold 14,105 Shares at a weighted average price of $0.84 per Share. On December 10, 2024, OPI VII sold 8,015 Shares at a weighted average price of $0.80 per Share. On December 10, 2024, WWH sold 2,085 Shares at a weighted average price of $0.80 per Share. On December 11, 2024, OPI VII sold 80 Shares at a price of $0.80 per Share. On December 11, 2024, WWH sold 20 Shares at a price of $0.80 per Share. On December 20, 2024, OPI VII sold 230,321 Shares at a price of $0.60 per Share. On December 20, 2024, WWH sold 1,986,892 Shares at a price of $0.60 per Share. The Reporting Persons undertake, upon request by the staff of the SEC or the Issuer to provide full information regarding the number of Shares sold at each separate price. Not applicable. As of December 20, 2024, OrbiMed Capital is believed to have ceased to be the beneficial owner of more than five percent of the outstanding Shares. In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI VII, pursuant to the terms of the limited partnership agreement of OPI VII. Pursuant to this agreement and relationship, OrbiMed GP has discretionary investment management authority with respect to the assets of OPI VII. Such authority includes the power to vote and otherwise dispose of securities held by OPI VII. The number of outstanding Shares attributable to OPI VII is 7,404,869 Shares. OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI VII, may be considered to hold indirectly 7,404,869 Shares. In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Advisors is the managing member of OrbiMed GP, pursuant to the terms of the limited liability company agreement of OrbiMed GP. Pursuant to these agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to the assets of OPI VII. Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by OPI VII. The number of outstanding Shares attributable to OPI VII is 7,404,869 Shares. OrbiMed Advisors, pursuant to its authority under the terms of the limited liability company agreement of OrbiMed GP, may also be considered to hold indirectly 7,404,869 Shares. In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Capital is the investment advisor to WWH and may be deemed to have voting and investment power over the securities held by WWH. Such authority includes the power of OrbiMed Capital to vote and otherwise dispose of securities held by WWH. Investors' Rights Agreement In addition, OPI VII, WWH, and certain other stockholders of the Issuer entered into an amended and restated investors' rights agreement with the Issuer (the "Investors' Rights Agreement"), dated as of August 21, 2019. Pursuant to the Investors' Rights Agreement and subject to the terms and conditions therein, the parties agreed that: Registration Rights Following the closing of the Issuer's initial public offering (the "IPO"), the holders of a certain number of Shares, or their transferees, will be entitled to the registration rights set forth below with respect to registration of the resale of such Shares under the Securities Act of 1933, as amended (the "Securities Act") pursuant to the Investors' Rights Agreement. Demand Registration Rights At any time beginning six months following the date of the underwriting agreement of the IPO, the holders of at least thirty percent (30%) of the registrable securities then outstanding of the Issuer may make a written request that the Issuer register at least thirty percent (30%) of the registrable securities then outstanding, subject to certain specified conditions and exceptions. The Issuer is required to use commercially reasonable efforts to effect the registration and will pay all registration expenses, other than underwriting discounts and commissions, related to any demand registration. The Issuer is not obligated to effect more than two of these registrations. Piggyback Registration Rights Whenever the Issuer proposes to file a registration statement under the Securities Act, including a registration statement on Form S-3 as discussed below, other than with respect to certain excluded registrations, the Reporting Persons will be entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of Shares included in the registration, to include Shares held by the Reporting Persons in the registration. Form S-3 Registration Rights At any time after the Issuer is qualified to file a registration statement on Form S-3 under the Securities Act, and subject to limitations and conditions specified in the Investors' Rights Agreement, holders of at least twenty-five percent (25%) of the Registrable Securities (as defined in the Investors' Rights Agreement) then outstanding may make a written request that the Issuer prepare and file a registration statement on Form S-3 covering their Shares, so long as the aggregate price to the public equals or exceeds $3,000,000. The Issuer is not obligated to effect more than two of these Form S-3 registrations in any 12-month period. The foregoing description of the Investors' Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full texts of the Investors' Rights Agreement, which is filed as Exhibit 2 and incorporated herein by reference. ------------------------------------------------------------------------------------------------------------------------------------ Exhibit Description ------------------------------------------------------------------------------------------------------------------------------------ 1. Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Capital LLC, and OrbiMed Capital GP VII LLC. ------------------------------------------------------------------------------------------------------------------------------------ 2. Amended and Restated Investors' Rights Agreement by and among the Issuer and certain of its stockholders, dated as of August 21, 2019 (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1 (File No. 333-236214), filed with the SEC on February 3, 2020). ------------------------------------------------------------------------------------------------------------------------------------ ORBIMED ADVISORS LLC /s/ Carl L. Gordon Carl L. Gordon/Member 12/26/2024 ORBIMED CAPITAL GP VII LLC /s/ Carl L. Gordon Carl L. Gordon/Member of the Managing Member 12/26/2024 ORBIMED CAPITAL LLC /s/ Carl L. Gordon Carl L. Gordon/Member 12/26/2024 EX-99.1 2 ss4277243_ex9901.htm JOINT FILING AGREEMENT

 

Exhibit 1

 

JOINT FILING AGREEMENT

 

The undersigned hereby agree that Amendment No. 5 to the Statement on Schedule 13D, dated December 20, 2024, with respect to the common stock of Passage BIO, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Amendment No. 5, and for the completeness and accuracy of the information concerning itself contained therein. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Joint Filing Agreement as of the 26th day of December 2024.

 

  ORBIMED ADVISORS LLC  
       
  By: /s/ Carl L. Gordon  
    Name: Carl L. Gordon  
    Title: Member  
       
  ORBIMED CAPITAL GP VII LLC  
       
  By: ORBIMED ADVISORS LLC, its managing member
       
  By: /s/ Carl L. Gordon  
    Name: Carl L. Gordon  
   

Title: Member of OrbiMed Advisors LLC

 

  
  ORBIMED CAPITAL LLC  
       
  By: /s/ Carl L. Gordon  
    Name: Carl L. Gordon  
    Title: Member